<--- Back to Details
First PageDocument Content
Eli Lilly and Company / Neurological disorders / Peripheral neuropathy / Polyneuropathy / Neuropathic pain / Taxane / Vincristine / Oxaliplatin / Gemcitabine / Chemistry / Health / Medicine
Date: 2013-09-27 13:43:52
Eli Lilly and Company
Neurological disorders
Peripheral neuropathy
Polyneuropathy
Neuropathic pain
Taxane
Vincristine
Oxaliplatin
Gemcitabine
Chemistry
Health
Medicine

Add to Reading List

Source URL: www.kup.at

Download Document from Source Website

File Size: 964,32 KB

Share Document on Facebook

Similar Documents

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Gemzar safely and effectively. See full prescribing information for Gemzar. GEMZAR (gemcitabine for injection), fo

DocID: 1u0Nb - View Document

Final Results of a Phase 1b of Tarextumab (OMP-59R5) (anti-Notch2/3 antibody) in Combination with Nab-paclitaxel and Gemcitabine (Nab P+Gem) in Patients (pts) with Untreated Metastatic Pancreatic Cancer (mPC): ALPINE Stu

DocID: 1t7ew - View Document

Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Colin Weekes,1

DocID: 1t6TW - View Document

Preclinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer Manuel Hidalgo*, Antonio Cubillo*, Robert Stagg**, Jakob Dupont**, Wan-Ching Yen**, Tim

DocID: 1t3Wy - View Document

A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)

DocID: 1sZz9 - View Document